INI-4001 + pembrolizumab

INI-4001 + pembrolizumab is an investigational combination therapy in early clinical development for advanced solid tumors. **INI-4001** is a small molecule agonist of toll-like receptor 7/8 (TLR7/8), delivered using a nanoparticle system designed to enhance immune activation while minimizing systemic toxicity. INI-4001 stimulates type I interferon (notably IFNα) production and activates antigen-presenting cells, resulting in enhanced T cell responses. **Pembrolizumab** is a monoclonal antibody checkpoint inhibitor that targets programmed cell death protein 1 (PD-1), preventing tumor-induced immunosuppression. The combination aims to increase anti-tumor immune responses by simultaneously activating innate (via TLR7/8) and adaptive (via PD-1 blockade) immunity. This combination is being investigated in a phase 1 trial for safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced solid tumors, with INI-4001 either alone or combined with pembrolizumab after initial monotherapy[1][2][3][4][5][7].